Tailoring drug therapy based on genotype

Journal of Pharmacy Practice

Volumn 25, Issue 4, 2012, Pages 413-416

  Cavallari, Larisa H ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

genotype; pharmacogenetics; pharmacogenomic; polymorphism

Indexed keywords

ABACAVIR; ANTITHROMBOCYTIC AGENT; ATOMOXETINE; AZATHIOPRINE; CARBAMAZEPINE; CARRIER PROTEIN; CELECOXIB; CETUXIMAB; CHEMOKINE RECEPTOR CCR5; CLOPIDOGREL; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; DNA; DRUG METABOLIZING ENZYME; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; GLUCURONOSYLTRANSFERASE 1A1; HLA B ANTIGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRINOTECAN; MARAVIROC; OXIDOREDUCTASE; RASBURICASE; THIOPURINE METHYLTRANSFERASE; TRASTUZUMAB; UNCLASSIFIED DRUG; VITAMINK EPOXIDE REDUCTASE COMPLEX 1; VORICONAZOLE; WARFARIN;

AMINO ACID SUBSTITUTION; BONE MARROW TOXICITY; BREAST CANCER; CANCER CHEMOTHERAPY; CORONARY ARTERY DISEASE; CORONARY STENT; DNA POLYMORPHISM; DRUG DISPOSITION; DRUG EFFICACY; DRUG EXPOSURE; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG RESPONSE; DRUG SENSITIVITY; DRUG TARGETING; FOOD AND DRUG ADMINISTRATION; GENOTYPE; HEMOLYSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LOW DRUG DOSE; MEDICAL DECISION MAKING; MYOPATHY; NEUTROPENIA; PHARMACOGENETICS; REVIEW; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; STEVENS JOHNSON SYNDROME; THROMBOCYTE AGGREGATION INHIBITION; TOXIC EPIDERMAL NECROLYSIS;

EID: 84865255225     PISSN: 08971900     EISSN: 15311937     Source Type: Journal    
DOI: 10.1177/0897190012448311     Document Type: Review

References (12)

1. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science. 1999 ; 286 (5439). 487-491
2. Evans WE, Hon YY, Bomgaars L, et al. Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. J Clin Oncol. 2001 ; 19 (8). 2293-2301 (Pubitemid 32366982)
3. Zhou SF, Liu JP, Chowbay B. Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev. 2009 ; 41: 89-295
4. Takahashi H, Kashima T, Nomoto S, et al. Comparisons between in-vitro and in-vivo metabolism of (S)-warfarin: catalytic activities of cDNA-expressed CYP2C9, its Leu359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes. Pharmacogenetics. 1998 ; 8 (5). 365-373 (Pubitemid 28475300)
5. Aithal GP, Day CP, Kesteven PJ, et al. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet. 1999 ; 353 (9154). 717-719 (Pubitemid 29103806)
6. Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009 ; 360 (4). 354-362
7. Rieder MJ, Reiner AP, Gage BF, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med. 2005 ; 352 (22). 2285-2293 (Pubitemid 40740552)
8. Limdi NA, Wadelius M, Cavallari L, et al. Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood. 2010 ; 115 (18). 3827-3834
9. Harries M, Smith I. The development and clinical use of trastuzumab (Herceptin). Endocr Relat Cancer. 2002 ; 9 (2). 75-85 (Pubitemid 34832161)
10. Loscher W, Klotz U, Zimprich F, et al. The clinical impact of pharmacogenetics on the treatment of epilepsy. Epilepsia. 2009 ; 50 (1). 1-23
11. Cavallari LH, Limdi NA. Warfarin pharmacogenomics. Curr Opin Mol Ther. 2009 ; 11 (3). 243-251
12. Ashley EA, Butte AJ, Wheeler MT, et al. Clinical assessment incorporating a personal genome. Lancet. 2010 ; 375 (9725). 1525-1535